Oncolinx is developing next-generation, targeted cancer therapeutics Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment. These therapies can be targeted to nearly any type of cancer and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.
Member count: 1-10

Investors 1

Mentions in press and media 1

14.11.2016Why These ...43North, part of New York Gove...Stories P...-bizjournal...